Tech Company Financing Transactions
Delix Therapeutics Funding Round
On 8/18/2026, Delix Therapeutics announced $85 million in Series C funding from Johnson & Johnson Development Corporation and private investors.
Transaction Overview
Company Name
Announced On
8/18/2026
Transaction Type
Venture Equity
Amount
$85,000,000
Round
Series C
Investors
Johnson & Johnson Development Corporation (Lead Investor)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Boston, MA 02139
USA
Boston, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Based on the discovery of a novel class of neuroplasticity-promoting therapeutics known as psychoplastogens, we are building a world class CNS company on a mission to broaden patient access to safe, fast-acting, and long-lasting medicines for many of the leading causes of disability worldwide.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Rus
Chief Medical Officer
Bigs Robertson
Chief Operating Officer
David Olson
Chief Scientific Officer
Kurt Rasmussen
Browse more venture capital transactions:
Prev: 8/18/2026: Sonic Fire Tech venture capital transaction
Next: 8/18/2026: Eco Gadgets Eservices venture capital transaction
Share this article
News on VC Transactions
We do our best to document every notable VC transaction. VC transactions reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs